President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

US Food and Drug Administration officials are changing the agency's standards for updated COVID-19 booster shots with focus ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit ...